Interleukin 1 – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Interleukin 1 (IL1) – Pipeline Review, H1 2020’, provides in depth analysis on Interleukin 1 (IL1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 (IL1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Oncology, Cardiovascular, Gastrointestinal, Musculoskeletal Disorders, Dermatology, Metabolic Disorders, Genetic Disorders, Central Nervous System, Ear Nose Throat Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders and Respiratory under development targeting Interleukin 1 (IL1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)

– The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

3SBio Inc

Bioiberica SAU

Devonian Health Group Inc

Johnson & Johnson

Komipharm International Co Ltd

Link Health Group

Mabpharm Ltd

Moderna Therapeutics Inc

Novartis AG

Omnitura Therapeutics Inc

Opsona Therapeutics Ltd

Peptinov SAS

R Pharm

Regeneron Pharmaceuticals Inc

Spherium Biomed SL

Swedish Orphan Biovitrum AB

Therapicon Srl

TWi Biotechnology Inc

XBiotech Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Interleukin 1 (IL1) Overview

Interleukin 1 (IL1) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Interleukin 1 (IL1) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 1 (IL1) Companies Involved in Therapeutics Development

Apexigen Inc

Link Health Group

Moderna Therapeutics Inc

Novartis AG

Omnitura Therapeutics Inc

Opsona Therapeutics Ltd

Peptinov SAS

R Pharm

Regeneron Pharmaceuticals Inc

Spherium Biomed SL

Swedish Orphan Biovitrum AB

XBiotech Inc

Interleukin 1 (IL1) Drug Profiles

AC-203 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bermekimab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

canakinumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein CR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LH-026 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit IL-1a for Atherosclerosis and Myocardial Infarction Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA-2752 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMN-54 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPV-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PUR-0110 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rilonacept Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPH-104 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOBI-006 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-15008 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 1 (IL1) Dormant Products

Interleukin 1 (IL1) Discontinued Products

Interleukin 1 (IL1) Product Development Milestones

Featured News & Press Releases

Oct 26, 2018: XBiotech announces new patents for bermekimab in the third quarter of 2018

Oct 22, 2018: TWi Biotechnology enrols first patient in Phase II AC-203 trial

Oct 05, 2018: Xbiotech announces enrollment completion in phase 2 multicenter study evaluating Bermekimab in patients with atopic dermatitis

Sep 26, 2018: XBiotech announces granting of European patent for treatment of inflammatory skin diseases

Sep 24, 2018: XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa

Sep 20, 2018: XBiotech announces addition of top dermatologist and researcher Dr. Alice Gottlieb to its team

Sep 13, 2018: XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis

Aug 27, 2018: Xbiotech announces publication of breakthrough findings for potential role of interleukin-1 alpha in risk for heart attacks

Aug 09, 2018: Castle Creek Pharmaceuticals receives FDA Fast Track Designation for Diacerein 1% ointment for treatment of Epidermolysis Bullosa Simplex

Jul 10, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa

Jun 25, 2018: Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment

Jun 22, 2018: Regeneron Regarding Royalty Agreement with Novartis for Canakinumab

May 22, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis

May 16, 2018: Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa

May 15, 2018: European Society of Cardiology consensus statement on inflammation in atherosclerosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by 3SBio Inc, H1 2020

Pipeline by Bioiberica SAU, H1 2020

Pipeline by Devonian Health Group Inc, H1 2020

Pipeline by Johnson & Johnson, H1 2020

Pipeline by Komipharm International Co Ltd, H1 2020

Pipeline by Link Health Group, H1 2020

Pipeline by Mabpharm Ltd, H1 2020

Pipeline by Moderna Therapeutics Inc, H1 2020

Pipeline by Novartis AG, H1 2020

Pipeline by Omnitura Therapeutics Inc, H1 2020

Pipeline by Opsona Therapeutics Ltd, H1 2020

Pipeline by Peptinov SAS, H1 2020

Pipeline by R Pharm, H1 2020

Pipeline by Regeneron Pharmaceuticals Inc, H1 2020

Pipeline by Spherium Biomed SL, H1 2020

Pipeline by Swedish Orphan Biovitrum AB, H1 2020

Pipeline by Therapicon Srl, H1 2020

Pipeline by TWi Biotechnology Inc, H1 2020

Pipeline by XBiotech Inc, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Dormant Products, H1 2020 (Contd..2), H1 2020

Dormant Products, H1 2020 (Contd..3), H1 2020

Dormant Products, H1 2020 (Contd..4), H1 2020

Dormant Products, H1 2020 (Contd..5), H1 2020

Discontinued Products, H1 2020

Discontinued Products, H1 2020 (Contd..1), H1 2020

Discontinued Products, H1 2020 (Contd..2), H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports